Pink SheetAstraZeneca PLC ’s Imfinzi became the second cancer immunotherapy approved for perioperative use in resectable non-small cell lung cancer (NSCLC) on 15 August, despite the US Food and Drug Administrat
Pink SheetEiger BioPharmaceuticals, Inc. ’s peginterferon lambda, Gilead Sciences, Inc. ’s magrolimab, Takeda Pharmaceutical Co. Ltd. ’s TAK-994 and Bavarian Nordic A/S ’s RSV vaccine are the latest entrants
ScripOrphan Drug Advantages Under Threat A recent publication in JAMA compared the sales of prescription drugs five years after launch and found that those with Orphan Drug Act designation were just as
Pink SheetBreadth of indication will be on the line when the US FDA’s Oncologic Drugs Advisory Committee weighs a new first-line prostate cancer claim for AstraZeneca PLC ’s PARP-inhibitor Lynparza (olaparib).